Tribute Pharmaceuticals to Host First Quarter 2015 Earnings Conference Call and Webcast Live on Tuesday, May 12, 2015

MILTON, ON / ACCESSWIRE / May 11, 2015 / Tribute Pharmaceuticals Canada Inc. (TSX Venture: TRX) will host a conference call and live webcast to discuss the results of the first quarter 2015, to be held Tuesday, May 12, 2015 at 9:00 AM Eastern Time.

To participate in this event, dial 877-407-0782 domestically, or 201-689-8567 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174022.

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com.

You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference ID # 13609659. The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on May 27, 2015.

About Tribute Pharmaceuticals Canada Inc.

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia(R) (diclofenac potassium for oral solution), Bezalip(R) SR (bezafibrate), Soriatane(R) (acitretin), NeoVisc(R) (1.0% sodium hyaluronate solution) Uracyst(R) (sodium chondroitin sulfate solution 2%), Fiorinal(R), Fiorinal(R) C, Visken(R), Viskazide(R), and Collatamp(R) G in the Canadian market. Additionally, NeoVisc(R) and Uracyst(R) are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to develop and commercialize Bezalip(R) SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval.

SOURCE: Investor Calendar

ReleaseID: 428737